Navigation Links
Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
Date:4/30/2008

SOUTH SAN FRANCISCO, Calif., April 30 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced that management will hold an investor conference call on Thursday, May 8, 2008 at 11:00 a.m. ET/8:00 a.m. PT to discuss financial results for the first quarter ended March 31, 2008.

Individual and institutional investors can access the call via (877) 440-5786 (U.S. and Canada) or (719) 325-4929 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
2. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
3. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
6. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
8. Onyx Pharmaceuticals Announces First Quarter 2008 Financial Results Teleconference and Webcast
9. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
10. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
11. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Michael Zasloff , MD, Ph.D., Professor ... Medicine, and Founder, Chairman and CEO of Enterin Inc. ... helped clarify the function of alpha-Synuclein (aS), the protein ... Denise Barbut , MD, FRCP, Co-Founder, President and ... of the study. Published in the Journal ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... Bock UK Ltd (Bock) announced a strategic partnership where Bock will ... enzyme technology, OPTIMASH® AD-100, has been shown to help biogas producers in the ...
(Date:6/28/2017)... ... June 28, 2017 , ... Studies indicate that replacing damaged brain cells with ... Parkinson’s disease. But what has not been determined is the optimal stage during differentiation ... results. , A new study coming out of Singapore, recently published in STEM CELLS ...
(Date:6/27/2017)... , ... June 27, 2017 , ... Biodex Medical Systems, ... ambulation aid in one device. This assistive aid lifts patients safely from a seated ... and motorized lift mechanics. The Mobility Assist is the latest in a line of ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):